Donislecel

Donislecel, sold under the brand name Lantidra, is a cellular therapy used to treat type 1 diabetes. It consists of allogeneic pancreatic islet cells taken from deceased donors and infused into a patient's hepatic portal vein in a single procedure, where the transplanted beta cells can secrete insulin and help regulate blood sugar. It is indicated for adults with type 1 diabetes who experience repeated severe episodes of low blood sugar despite intensive disease management and who are unable to reach their target blood sugar control. In clinical trials involving thirty participants, twenty-one achieved independence from insulin injections for at least one year, with some remaining insulin-free for more than five years. The United States Food and Drug Administration approved donislecel in June 2023, the first cellular therapy approved to treat type 1 diabetes. It is developed by CellTrans, Inc.